/
BBIO
$74.08+$2.07 (+2.87%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$13.8B
196M shares
52-week range
$41.80 – $84.94
75% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change+$10.47
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| Cost of revenue | $0 | $2.5M | $0 | $3.1M | $3.4M | $2.4M | $3.9M | $28.3M |
| Gross profit | $0 | $38.1M | $8.2M | $66.6M | $74.2M | $6.9M | $218.0M | $473.8M |
| Gross margin | — | 93.8% | 100.0% | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| R&D | $140.1M | $209.9M | $337.0M | $451.0M | $399.5M | $455.7M | $506.5M | $477.5M |
| Operating income | −$183.7M | −$266.2M | −$474.5M | −$576.6M | −$512.2M | −$607.4M | −$593.0M | −$569.1M |
| EBITDA | −$183.4M | −$279.0M | −$467.4M | −$533.8M | −$397.4M | −$565.5M | −$436.8M | −$672.9M |
| Net income | −$130.7M | −$260.4M | −$448.7M | −$562.5M | −$481.2M | −$643.2M | −$535.8M | −$729.3M |
| Net margin | — | -642.1% | -5439.7% | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (diluted) | -1.42 | -2.48 | -4.10 | -3.90 | -3.35 | -3.95 | -2.88 | -3.79 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $969M | $-2.17 | $-3.03–$-1.41 | 13 |
| 2027 | $1.6B | $0.54 | $-5.40–$8.81 | 12 |
| 2028 | $2.4B | $3.67 | $-0.02–$6.84 | 14 |
| 2029 | $3.5B | $7.47 | $6.33–$8.77 | 8 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
www.bridgebio.com- Employees
- 839
- IPO / List date
- Jun 27, 2019
- HQ
- PALO ALTO, CA
Held by traders on TradeandTell
No one on the platform currently holds BBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 365,772 | $27.2M |
| Bridgewater Associatesas of 2026-03-31 | 259,459 | $19.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BBIO yet.
